CAIX has been extensively studied as a potential therapeutic target in oncology, owing to its specificity to cancer cells—it has a very restricted expression in the normal stomach and gut epithelial cells [76] but is strongly upregulated in many different types of tumour tissue [77]. This evidence concerns the gene CA9 and cancer.